Lab-grown Vessel Could Speed Dialysis Access for Women
A new trial suggests women may achieve usable dialysis access months earlier than with traditional fistula surgery.
Updated on Oct. 28, 2026 in Stroke
Live Poll
Do you trust new medical technologies over established surgical procedures for your healthcare?
Humacyte reported interim Phase 3 trial results showing a lab-grown vessel reached usable dialysis access significantly faster in women compared to standard fistula surgery. This development could eventually offer an alternative for patients struggling with slow maturation times and high infection risks associated with traditional access methods.
Why it matters
Women often face lower maturation rates for standard arteriovenous fistulas due to smaller blood vessel size, often forcing reliance on high-infection-risk central line catheters. This trial suggests a new lab-grown option could reduce time on these catheters by allowing earlier, safer access for dialysis.
In an interim Phase 3 trial of 80 women, participants using a lab-grown vessel achieved usable dialysis access at a median of 1.7 months, compared to 5.3 months for those receiving standard fistulas. These preliminary findings have not yet been published in a peer-reviewed journal.
The players
Humacyte
A biotechnology company developing lab-grown tissue-engineered therapies for vascular and trauma applications.
American Society of Nephrology
A professional organization that provides a forum for researchers and clinicians to share advances in kidney care.
FDA
The federal agency responsible for evaluating the safety and efficacy of new medical devices and treatments.
The details
Surgeons create access by connecting the lab-grown vessel, currently approved as Symvess for vascular trauma, between an artery and a vein. A traditional fistula is formed by surgically joining a patient's own artery and vein in the arm. The lab-grown option yielded 220 days catheter-free over one year, compared to 129 days for the standard group, while also recording lower infection rates of 6 per 100 patient-years versus 23 per 100 patient-years.
Timeline
December 2024: The FDA approved the vessel as Symvess for treating vascular trauma.
June 2026: Humacyte announced initial topline results from the trial.
October 2026: These results were presented at the American Society of Nephrology meeting in Denver.
Q4 2026: Humacyte plans to submit an FDA application for dialysis access label expansion.
Health Landscape
This development addresses long-standing challenges with the current standard of care for dialysis access, specifically the high failure and infection rates observed with traditional arteriovenous fistulas. It represents an attempt to bypass existing anatomical hurdles that frequently complicate patient care.
If you or a family member are preparing for dialysis, the slow maturation of traditional fistulas is a common hurdle worth discussing with a surgeon. Ask your nephrologist about current options for vascular access and whether clinical trials for emerging technologies might be relevant to your care.
The takeaway
Lab-grown vessels may offer a faster path to dialysis access for women, potentially reducing reliance on high-risk catheters. Patients should talk with their care team about the latest vascular access options, as individual anatomy can significantly influence which surgical approach is most appropriate.
What happens next
Humacyte plans to submit an application to the FDA to expand the indication of Symvess to include dialysis access during the fourth quarter of 2026.
Further reading
Learn more about the latest research in our Stroke section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust new medical technologies over established surgical procedures for your healthcare?
